Navigation Links
EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
Date:10/2/2008

priority clinical oncology programs. Listing our shares on the Nasdaq Capital Market extends our compliance period by six months, during which time we expect to make further clinical progress and will continue to pursue a development partner for our Aurora/angiogenesis program. We will also continue to explore available options for regaining compliance with Nasdaq listing requirements."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assum
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed to Present at BIO CEO and Investor Conference
6. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
7. EntreMed Announces 2008 Corporate and Clinical Program Priorities
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... , April 24, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics including high value and difficult ... follow-on public offering of 6,000,000 shares of its common ... per share. Of the shares being offered, 2,610,000 are ... are being offered by existing stockholders. Pfenex will not ...
(Date:4/24/2015)... Seoul Semiconductor announced the expansion of its ... lighting market. In recent months, there have ... emerging markets such as Russia, South America, and ... such as streetlight and area lighting, tunnel lighting, ... in 2005 the Acrich technology from Seoul Semiconductor ...
(Date:4/23/2015)... 23, 2015 /CNW/ - A new and innovative service ... North America,s largest packaging ... Silver in the "Sustainability, service" category of the ... "Competitor Comparison" is a service that scores clients, ... Global peers. This benchmarking process shows clients how ...
(Date:4/23/2015)... 23, 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology and medical ... and the United States , ... the first quarter of 2015 after the New York ... will be Thursday morning, May 14, 2015 Shanghai time). ...
Breaking Biology Technology:Pfenex Inc. Announces Pricing Of Follow-on Offering 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3
... AUXL ) today announced that executive management will ... held June 4-7, 2012 at the Grand Hyatt in New ... is scheduled to present an overview of the Company and ... 4, 2012. A breakout session will be held following the ...
... PARSIPPANY, N.J., May 29, 2012  Watson Pharmaceuticals, Inc. (NYSE: ... company, announced today that Paul Bisaro, Watson,s President and ... of the Company,s business at the Goldman Sachs Global ... 8:00AM Pacific Time at the Terranea Resort in Rancho ...
... conditions such as multiple sclerosis and heart and liver ... and life sciences facilities opened yesterday by HRH, the ... unveil plaques this afternoon at the $85 million Scottish ... facility, Nine, in Edinburgh. The University of ...
Cached Biology Technology:Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference 2Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference 3Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference 4Watson to Present at Goldman Sachs Global Healthcare Conference 2012 2Scotland opens stem cell research center and bio-medical incubator 2
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... smart wallets is underway to early access pre-order customers. ... includes usage at retail outlets including Walmart, Target, AT&T, ... report Wocket was accepted at all outlets and very ...
(Date:3/31/2015)... March 31, 2015  Elephant Talk Communications Corp. (NYSE ... provider of Software Defined Network Architecture (ET Software DNA® ... revenue of approximately $20.4 million for the year ended ... million for the year ended December 31, 2013. ... Company had completed its multi-year transition away from its ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... Hackensack, NJ (June 29, 2011) Researchers at the John ... of social support to distress after stem cell transplants. Scott ... the John Theurer Cancer Center at Hackensack University Medical Center ... Labay from Mt. Sinai. The study was published in the ...
... CORPUS CHRISTI Just as corn and ... discovered multi-beneficial uses and applications, Texas AgriLife Research scientists ... "It,s a huge, untapped source of fuel, food, ... a crop physiologist at the Texas AgriLife Research and ...
... rebirth, but if it comes too early, it can threaten ... of Alberta study shows that climate change over the past ... and trees into earlier blooming times, making them more vulnerable ... of A PhD candidate Elisabeth Beaubien and her supervisor, professor ...
Cached Biology News:John Theurer Cancer Center BMT researchers highlight the importance of social support 2Microalgae could be Texas' next big cash crop 2Microalgae could be Texas' next big cash crop 3
... Immunogen: Synthetic phosphopeptide corresponding to ... Ser603 residue of rat Synapsin ... synapsin I when phosphorylated at ... Rat (positive control: rat brain ...
EMBP (FL-222)...
... PhosphatidylEthanolamine-Binding Protein (PEBP) does not share ... inhibitors. PEBP is expressed in ... ovary, muscle, and stomach. One ... is exerting inhibitory activity against several ...
Anti-Rsk2/MAPKAP Kinase 1b, #0 SK2/MAPKAP K1 beta Smartpool&t 3T3 cell lysate Non-specific Control Pool , #D 1X Universal Buffer...
Biology Products: